• 1
    Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 37683785.
  • 2
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press.
  • 3
    Olsen E, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 17131722.
  • 4
    Kim YH, Willemze R, Pimpinelli N et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479484.
  • 5
    Whittaker SJ, Marsden JR, Spittle M, Russell Jones R. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003; 149: 10951107.
  • 6
    Trautinger F, Knobler R, Willemze R et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer 2006; 42: 10141030.
  • 7
    Dummer R. Primary cutaneous lymphomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007; 18(Suppl 2): ii61ii62.
  • 8
    Iwatsuki K, Kawai K, Ohtsuka M et al. Guidelines for the management of cutaneous malignant tumors II: cutaneous lymphomas. Jpn J Dermatol 2009; 119: 11891211.
  • 9
    Kim EJ, Hess S, Richardson SK et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115: 789812.
  • 10
    Bunn PA Jr, Huberman MS, Whang-Peng J et al. Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination. Ann Intern Med 1980; 93: 223230.
  • 11
    Sausville EA, Eddy JL, Makuch RW et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups. Ann Intern Med 1988; 109: 372382.
  • 12
    Olsen EA, Whittaker S, Kim YH et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011; 29: 25982607.
  • 13
    Vonderheid EC, Bernengo MG, Burg G et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002; 46: 95106.
  • 14
    Senff NJ, Willemze R. The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: results and comparison with the system used by the Dutch Cutaneous Lymphoma Group. Br J Dermatol 2007; 157: 12051211.
  • 15
    Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol 1991; 79: 428437.
  • 16
    Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: cotswolds meeting. J Clin Oncol 1989; 7: 16301636.
  • 17
    Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int 2000; 50: 696702.
  • 18
    Suzuki S, Ito K, Ito M, Kawai K. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome. J Dermatol Sci 2010; 57: 3743.
  • 19
    Sawada Y, Hino R, Hama K et al. Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood 2011; 117: 39613967.
  • 20
    Suzuki R, Suzumiya J, Yamaguchi M et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 2010; 21: 10321040.
  • 21
    Suzuki R, Nakamura S, Suzumiya J et al. Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor). Prognostication and categorization according to anatomic sites of involvement. Cancer 2005; 104: 10221031.
  • 22
    Agar NS, Wedgeworth E, Crichton S et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary sundrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28: 47304739.
  • 23
    Benner MF, Willemze R. Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol 2009; 145: 13991404.
  • 24
    Willemze R, Jansen PM, Cerroni L et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008; 111: 838845.
  • 25
    Zinzani PL, Quaglino P, Pimpinelli N et al. Prognostic factors in primary cutaneous B-cell lymphoma:the Italian study group for cutaneous lymphoma. J Clin Oncol 2006; 24: 13761382.
  • 26
    Sneff NJ, Hoefnagel JJ, Jansen PM et al. Reclassification of 300 primary cutaneous B-cell lymphoma according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol 2007; 25: 15811587.
  • 27
    Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome. Arch Dermatol 2003; 139: 857866.
  • 28
    Bekkenk MW, Jansen PM, Meijer CJ, Willemze R. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol 2004; 15: 10971108.
  • 29
    Stadler R, Otte HG, Luger T et al. Prospective randomized multicenter clinical trial on the use of interferonα 2a plus acitretin versus interferonα-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 35783581.
  • 30
    Stadler R, Kremer A, Luger T, Sterry W. Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotehrapy in patients with cutaneous T-cell lymphoma, stage I and II. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings, 2006; 24: 7541.
  • 31
    Kaye FJ, Bunn PA Jr, Steinberg SM et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321: 17841790.
  • 32
    Child FJ, Mitchell TJ, Whittaker SJ, Scarisbrick JJ, Seed PT, Russell-Jones R. A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clin Exp Dermatol 2004; 29: 231236.
  • 33
    Prince HM, Duvic M, Martin A et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 18701877.
  • 34
    Toro JR, Beaty M, Sorbara L et al. Gamma delta T-cell lymphoma of the skin: a clinical, microscopic, and molecular study. Arch Dermatol 2000; 136: 10241032.
  • 35
    Santucci M, Pimpinelli N, Massi D et al. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer 2003; 97: 610627.
  • 36
    Lu D, Patel KA, Duvic M, Jones D. Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas. J Cutan Pathol 2002; 29: 465472.
  • 37
    Toro JR, Liewehr DJ, Pabby N et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 2003; 101: 34073412.
  • 38
    Bekkenk MW, Vermeer MH, Jansen PM et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood 2003; 102: 22132219.
  • 39
    Berti E, Tomasini D, Vermeer MH, Alessi E, Willemze R. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 1999; 155: 483492.
  • 40
    Setoyama M, Katahira Y, Kanzaki T. Clinicopathologic analysis of 124 cases of adult T-cell leukemia/lymphoma with cutaneous manifestations: the smouldering type with skin manifestations has a poorer prognosis than previously thought. J Dermatol 1999; 26: 785790.
  • 41
    Takahashi K, Tanaka T, Fujita M et al. Cutaneous-type adult T-cell leukemia/lymphoma. A unique clinical feature with monoclonal T-cell proliferation detected by Southern blot analysis. Arch Dermatol 1988; 124: 399404.
  • 42
    Johno M, Ohishi M, Kojo Y, Yamamoto S, Ono T. Cutaneous manifestations of adult T-cell leukemia/lymphoma. Gann Monogr Cancer Res 1992; 39: 3342.
  • 43
    Amano M, Kurokawa M, Ogata K et al. New entity, definition and diagnostic criteria of cutaneous adult T-cell leukemia/lymphoma: human T-lymphotropic virus type 1 proviral DNA load can distinguish between cutaneous and smoldering types. J Dermatol 2008; 35: 270275.
  • 44
    Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES. Epstein–Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8–9 September 2008. Ann Oncol 2009; 20: 14721482.
  • 45
    Herling M, Jones D. CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol 2007; 127: 687700.
  • 46
    Sneff NJ, Noordijk EM, Kim YH et al. European Organization for Research and Treatment of Cancer and International. Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008; 112: 16001609.